Vidyashri Hattigoudar: Essentials and Management of Hemophilia A
Vidyashri Hattigoudar, Clinical Manager at Shakti Hospital, shared a post on LinkedIn:
“Hemophilia A-Understanding the Bleeding Disorder
Hemophilia A is a rare inherited bleeding disorder caused by a deficiency or reduced activity of clotting factor VIII (FVIII).
Normally, clotting factors work together to stop bleeding. In Hemophilia A, insufficient FVIII makes it difficult for the blood to form a stable clot.
Common Features
- Prolonged bleeding after injuries, dental procedures, or surgery
- Easy bruising
- Recurrent bleeding into joints, especially knees, ankles, and elbows
- Bleeding into muscles and soft tissues
- In severe cases, bleeding may occur spontaneously
Why does it happen?
Hemophilia A is usually caused by a change (mutation) in the F8 gene, which provides instructions for making factor VIII. It is typically X-linked, meaning it mainly affects males, while females may be carriers.
Treatment and Management
Treatment aims to prevent and control bleeding. Options may include:
- Factor VIII replacement therapy
- Non-factor therapies such as emicizumab for appropriate patients
- Treatment plans tailored according to severity and individual needs
- Regular monitoring and comprehensive hemophilia care
Key message: Hemophilia A is a lifelong condition, but with early diagnosis, appropriate treatment, and proper care, people with Hemophilia A can live active and fulfilling lives.”
Stay updated with Hemostasis Today.
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026
-
Oct 12, 2026, 10:36PAI-1 Inhibition as a New Strategy for Enhancing Fibrinolysis and Clot Resolution
-
Oct 12, 2026, 07:39Emmanuel J Favaloro: 100 Years of von Willebrand Disease and the Importance of Local Diagnosis and Management
-
Oct 12, 2026, 07:39Post-Stroke Fatigue Trajectories – 38% Recovered at 12 Months, While 16% Developed New Fatigue – International Journal of Stroke